Novartis And Idenix Seek European Approval Of Telbivudine (LDT600) For (Hep C Treatment)

Novartis And Idenix Seek European Approval Of Telbivudine (LDT600) For
Medical News Today - Novartis and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than

Pharmacy Benefit
Managed Healthcare Executive - HEPATITIS B AND C are serious viral diseases that can lead to lifelong infection, cirrhosis, liver cancer, liver failure and death. They often produce chronic, hidden infections. An estimated 1.25 million Americans are infected with hepatitis B, and

CROI: Rapid response predicts success in HIV/HCV coinfected patients
Aidsmap - Virological response to hepatitis C therapy after four weeks appears to predict who will have a successful response to a full course of treatment in HIV-positive people coinfected with hepatitis C genotypes 1 or 3, according to findings from two